公开(公告)号：US20210317218A1

公开(公告)日：2021-10-14

申请号：US17150789

申请日：2021-01-15

Applicant: CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. ,  NEWCASTLE INNOVATION LTD.

Inventor： Angel LOPEZ ,  Paul FOSTER

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/00 ,  A61K31/57 ,  A61K39/395

Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.

公开(公告)号：US20180155435A1

公开(公告)日：2018-06-07

申请号：US15661652

申请日：2017-07-27

Applicant: Central Adelaide Local Health Network ,  Newcastle Innovation Ltd.

Inventor： Angel LOPEZ ,  Paul Foster

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2866 ,  A61K31/00 ,  A61K31/57 ,  A61K39/3955 ,  A61K45/06

Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.

公开(公告)号：US20200055943A1

公开(公告)日：2020-02-20

申请号：US16362581

申请日：2019-03-22

Applicant: CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. ,  NEWCASTLE INNOVATION LTD.

Inventor： Angel LOPEZ ,  Paul FOSTER

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/57 ,  A61K31/00 ,  A61K45/06

Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.

公开(公告)号：US20160022197A1

公开(公告)日：2016-01-28

申请号：US14775909

申请日：2014-03-17

Applicant: NEWCASTLE INNOVATION LTD

Inventor： Saadallah Ramadan ,  Gorane Santamaria ,  Peter Malycha ,  Carolyn Mountford ,  David Clarke

IPC: A61B5/00 ,  G01R33/483 ,  G01R33/46 ,  G01N33/483 ,  A61B5/055

CPC classification number: A61B5/4312 ,  A61B5/055 ,  A61B5/7282 ,  A61B5/742 ,  A61B2576/02 ,  C12Q1/6886 ,  C12Q2563/143 ,  C12Q2565/601 ,  G01N33/4833 ,  G01N2405/00 ,  G01R33/46 ,  G01R33/4633 ,  G01R33/465 ,  G01R33/483 ,  G01R33/485

Abstract: A method and system for detecting the presence of BRCS carriers in breast tissue, comprises obtaining spectral data from breast tissue using a magnetic resonance spectroscopy device and producing spectral data by said device which provides chemical markers to enable detection of whether the breast tissue contains BRCA carriers.

Abstract translation: 一种用于检测乳腺组织中BRCS载体的存在的方法和系统，包括使用磁共振光谱仪从乳腺组织获得光谱数据，并通过所述装置产生光谱数据，所述装置提供化学标记，以检测乳腺组织是否含有BRCA载体 。

公开(公告)号：US20150232564A1

公开(公告)日：2015-08-20

申请号：US14638579

申请日：2015-03-04

Applicant: CENTRAL ADELAIDE LOCAL HEALTH NEWORK INC. ,  Newcastle Innovation Ltd.

Inventor： Angel Lopez ,  Paul Foster

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2866 ,  A61K31/00 ,  A61K31/57 ,  A61K39/3955 ,  A61K45/06

Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.

Abstract translation: 降低具有升高水平的哺乳动物的肺中的IL-4和/或IL-13水平的方法包括向哺乳动物施用有效量的能够阻断所有的结合的受体阻断剂的步骤 三个IL-3，IL-5和GM-CSF转移到共培养链上，从而降低IL-4和/或IL-13水平。

公开(公告)号：US20240076393A1

公开(公告)日：2024-03-07

申请号：US18449598

申请日：2023-08-14

Applicant: CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. ,  NEWCASTLE INNOVATION LTD.

Inventor： Angel LOPEZ ,  Paul FOSTER

IPC: C07K16/28 ,  A61K31/00 ,  A61K31/57 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2866 ,  A61K31/00 ,  A61K31/57 ,  A61K39/3955 ,  A61K45/06

Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels.